通过抑制细胞周期检查点介质 WEE1 靶向 ATRX 缺失。
Targeting ATRX Loss through Inhibition of the Cell-Cycle Checkpoint Mediator WEE1.
机构信息
Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Colket Translational Research Building, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
出版信息
Cancer Res. 2020 Feb 1;80(3):375-376. doi: 10.1158/0008-5472.CAN-19-3587.
In this issue of , Liang and colleagues perform a genome-wide CRISPR-Cas9-negative loss-of-function screen and identify kinase as a therapeutic vulnerability in cells depleted of the chromatin remodeler gene. Because ATRX mutations are frequently mutated across a variety of pediatric and adult malignancies, this work may contribute to the preclinical rationale for a precision medicine trial of the WEE1 inhibitor AZD1775 (adavosertib) for patients whose tumors demonstrate ATRX loss..
本期 杂志中，梁教授及其同事进行了一项全基因组 CRISPR-Cas9 阴性功能丧失筛选实验，发现激酶是耗尽 染色质重塑基因的细胞中的一个治疗弱点。由于 ATRX 突变在多种儿科和成人恶性肿瘤中经常发生突变，这项工作可能为针对肿瘤表现出 ATRX 缺失的患者的 WEE1 抑制剂 AZD1775（adavosertib）的精准医学试验提供临床前理论依据。
Zotero 插件